Fingerprint
Dive into the research topics of 'MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours
Richard Wilson, Mark Middleton, Jennifer Houlden, Sandra Van Schaeybroeck, Christian Rolfo, Elena Elez, Julien Taieb, Thierry Andre, alberto Bardelli, Pierre Laurent=puig, Josef Tabernero, Marc Peeters, Tim Maughan, C Roberts, Sharon Love, Mark Lawler, Manuel Salto-Tellez, Margaret Grayson, Vlad Popovici, Federica Di Nicolantonio
Research output: Contribution to journal › Meeting abstract › peer-review